Adès L, Guardiola P, Sociè G
Service d'Hématologie-Greffe de Moelle, Hôpital Saint Louis, Paris, France.
Blood Rev. 2002 Jun;16(2):135-46. doi: 10.1054/blre.2002.0010.
With increased number of patients surviving on the long term, late effect after allogeneic hematopoietic stem cell transplantation have become of major clinical importance. Among these late effect, second malignancies have increasingly been recognized in the recent years. It has been usual to divide the problem of secondary malignancies following hematopoietic stem cell transplantation into three groups, i.e. leukemia, lymphoma and solid tumors. Recent clinical and biological data on these three types of malignancies, occurring after allogeneic stem cell transplantation, are summarized in this review. We will focus here only on second malignancies after allogeneic stem cell transplantation with particular emphasis on recent development on the pathogenesis, and early diagnosis, and treatment of these transplant-related complications.
随着长期存活患者数量的增加,异基因造血干细胞移植后的晚期效应已成为主要的临床问题。在这些晚期效应中,继发性恶性肿瘤近年来越来越受到关注。通常将造血干细胞移植后的继发性恶性肿瘤问题分为三组,即白血病、淋巴瘤和实体瘤。本文综述了异基因干细胞移植后这三种恶性肿瘤的最新临床和生物学数据。我们将重点关注异基因干细胞移植后的继发性恶性肿瘤,特别强调这些移植相关并发症在发病机制、早期诊断和治疗方面的最新进展。